Amneal Pharmaceuticals (AMRX) Current Assets (2017 - 2026)

Amneal Pharmaceuticals' Current Assets history runs 10 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Current Assets rose 19.03% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 19.03% YoY), while the FY2025 annual figure was $1.9 billion, up 20.37% from the prior year.
• Current Assets was $1.8 billion for Q1 2026 at Amneal Pharmaceuticals, down from $1.9 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.9 billion in Q4 2025 to a low of $1.3 billion in Q1 2023.
• Historically, Current Assets has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Current Assets dropped 10.9% in 2022, then increased 21.49% in 2025.
• A 5-year view of Current Assets shows it stood at $1.4 billion in 2022, then retreated by 2.41% to $1.4 billion in 2023, then grew by 15.24% to $1.6 billion in 2024, then advanced by 20.37% to $1.9 billion in 2025, then slipped by 5.93% to $1.8 billion in 2026.
• The last three Current Assets figures came in at $1.8 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.8 billion (Q3 2025), per Business Quant data.